Conatus Pharmaceuticals (CNAT) Stock Price Down 7.3%

Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) were down 7.3% on Wednesday . The company traded as low as $3.22 and last traded at $3.54. Approximately 441,788 shares changed hands during trading, a decline of 34% from the average daily volume of 673,924 shares. The stock had previously closed at $3.30.

A number of analysts recently weighed in on CNAT shares. Zacks Investment Research cut shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. S&P Equity Research increased their price target on shares of Conatus Pharmaceuticals from $5.02 to $5.69 in a research note on Wednesday, January 24th. Roth Capital started coverage on shares of Conatus Pharmaceuticals in a research note on Thursday, February 8th. They set a “buy” rating and a $20.00 price target for the company. Oppenheimer started coverage on shares of Conatus Pharmaceuticals in a research note on Thursday, March 1st. They set a “buy” rating and a $16.00 price target for the company. Finally, ValuEngine upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $12.00.

How to Become a New Pot Stock Millionaire

The company has a market capitalization of $104.61, a price-to-earnings ratio of -5.97 and a beta of 1.16. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.82 and a current ratio of 2.82.



Conatus Pharmaceuticals (NASDAQ:CNAT) last released its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. Conatus Pharmaceuticals had a negative net margin of 49.17% and a negative return on equity of 61.58%. The company had revenue of $8.80 million during the quarter, compared to analysts’ expectations of $9.60 million. research analysts expect that Conatus Pharmaceuticals will post -0.71 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in CNAT. MPM Asset Management LLC lifted its stake in shares of Conatus Pharmaceuticals by 76.3% in the 4th quarter. MPM Asset Management LLC now owns 2,101,171 shares of the biotechnology company’s stock worth $9,707,000 after acquiring an additional 909,091 shares during the period. State Street Corp purchased a new position in shares of Conatus Pharmaceuticals in the 2nd quarter valued at about $2,092,000. BlackRock Inc. increased its holdings in shares of Conatus Pharmaceuticals by 6.2% in the 4th quarter. BlackRock Inc. now owns 1,593,395 shares of the biotechnology company’s stock valued at $7,362,000 after purchasing an additional 93,015 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Conatus Pharmaceuticals by 26.2% in the 4th quarter. Geode Capital Management LLC now owns 429,556 shares of the biotechnology company’s stock valued at $1,983,000 after purchasing an additional 89,179 shares in the last quarter. Finally, Alambic Investment Management L.P. increased its holdings in shares of Conatus Pharmaceuticals by 259.7% in the 4th quarter. Alambic Investment Management L.P. now owns 102,501 shares of the biotechnology company’s stock valued at $474,000 after purchasing an additional 74,001 shares in the last quarter. Institutional investors own 38.71% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/04/25/conatus-pharmaceuticals-cnat-stock-price-down-7-3.html.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply